Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209779 | 0.88 | CHEK1 (0.77) | CHEK1MAPT | |
| SCHEMBL4206749 | 0.84 | CHEK1 (0.65) | CHEK1ALDH1A1HPGDKDM4E | |
| SCHEMBL4215417 | 0.83 | CHEK1 (0.70) | CHEK1MAPTKMT2AMEN1 | |
| SCHEMBL13951992 | 0.82 | CHEK1 (0.56) | CHEK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL4208133 | 0.81 | CHEK1 (0.67) | CHEK1 | |
| SCHEMBL4223830 | 0.79 | CHEK1 (0.63) | CHEK1ALDH1A1PKMHPGDKDM4E | |
| SCHEMBL4224511 | 0.79 | CHEK1 (0.63) | CHEK1MAPTKMT2A | |
| SCHEMBL4206514 | 0.78 | CHEK1 (0.60) | CHEK1ALDH1A1PKMHPGDKMT2A | |
| SCHEMBL4219794 | 0.78 | CHEK1 (0.62) | CHEK1ALDH1A1PKMHPGDKMT2A | |
| SCHEMBL4218805 | 0.78 | CHEK1 (0.73) | CHEK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | claimed |
| JP-2007502308-A | — | — | 2007-02-08 | — | — | JP | claimed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | claimed |
| CN-1867557-A | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | CN | claimed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | claimed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| WO-2007105854-A1 | NOVEL LIPOIC ACID CONJUGATED COMPOUNDS AND SKIN EXTERNAL APPLICATIONS CONTAINING THEREOF | HAN-BUL COSMETICS CO., LTD. (KR) | 2007-09-20 | — | — | WO | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
| CN-1867557-A | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | CN | disclosed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | CHEK1 297/4885ALDH1A1 266/4885PKM 1577/4885 |
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | CHEK1 602/4885ALDH1A1 876/4885PKM 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.